Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of …
C Webers, A Ortolan, A Sepriano, L Falzon… - Annals of the …, 2023 - ard.bmj.com
Objective To update the evidence on efficacy and safety of biological disease-modifying
antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) to inform the …
antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) to inform the …
Assessing immunogenicity of biologic drugs in inflammatory joint diseases: progress towards personalized medicine
Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but
a substantial proportion of patients either do not respond to treatment or lose response over …
a substantial proportion of patients either do not respond to treatment or lose response over …
Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to …
C Krieckaert, B Hernández-Breijo, JE Gehin… - RMD open, 2022 - rmdopen.bmj.com
The objectives of this review were to collect and summarise evidence on therapeutic drug
monitoring (TDM) of biopharmaceuticals in inflammatory rheumatic and musculoskeletal …
monitoring (TDM) of biopharmaceuticals in inflammatory rheumatic and musculoskeletal …
Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview
YJ Song, SW Nam, CH Suh, JY Choe… - Expert Opinion on Drug …, 2023 - Taylor & Francis
ABSTRACT Introduction As of May 2023, 19 and 18 biosimilars have been approved for the
treatment of rheumatoid arthritis (RA) by the European Medicines Agency (EMA) and United …
treatment of rheumatoid arthritis (RA) by the European Medicines Agency (EMA) and United …
Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies
Importance There are conflicting data on the association of antidrug antibodies with
response to biologic disease–modifying antirheumatic drugs (bDMARDs) in rheumatoid …
response to biologic disease–modifying antirheumatic drugs (bDMARDs) in rheumatoid …
Proactive therapeutic drug monitoring of vincristine in pediatric and adult cancer patients: current supporting evidence and future efforts
CY Wu, GT Li, CC Chu, HL Guo, WR Fang, T Li… - Archives of …, 2023 - Springer
Vincristine (VCR), an effective antitumor drug, has been utilized in several polytherapy
regimens for acute lymphoblastic leukemia, neuroblastoma and rhabdomyosarcoma …
regimens for acute lymphoblastic leukemia, neuroblastoma and rhabdomyosarcoma …
Anti-drug antibodies in the biological therapy of autoimmune rheumatic diseases
O Pizano-Martinez, E Mendieta-Condado… - Journal of Clinical …, 2023 - mdpi.com
Autoimmune rheumatic diseases are a cluster of heterogeneous disorders that share some
clinical symptoms such as pain, tissue damage, immune deregulation, and the presence of …
clinical symptoms such as pain, tissue damage, immune deregulation, and the presence of …
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
I Jyssum, JE Gehin, J Sexton, EK Kristianslund… - …, 2024 - academic.oup.com
Objectives To explore associations between serum adalimumab level, treatment response
and drug survival in order to identify optimal drug levels for therapeutic drug monitoring of …
and drug survival in order to identify optimal drug levels for therapeutic drug monitoring of …
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR …
MK Brun, JE Gehin, KH Bjørlykke, DJ Warren… - The Lancet …, 2024 - thelancet.com
Background Antidrug antibodies to TNF inhibitors might affect clinical outcomes. Proactive
therapeutic drug monitoring allows for early detection of antidrug antibodies and might …
therapeutic drug monitoring allows for early detection of antidrug antibodies and might …
Individualized patient care through model-informed precision dosing: reflections on training future practitioners
R Jelliffe, J Liu, GL Drusano, MN Martinez - The AAPS Journal, 2022 - Springer
Prior to his passing, Dr. Roger Jelliffe, expressed the need for educating future physicians
and clinical pharmacists on the availability of computer-based tools to support dose …
and clinical pharmacists on the availability of computer-based tools to support dose …